Member Info for SYN00GOLD

Strong start to the day on Finnish market, bodes well for swift return to normality from Juho's botched up raise technique. However, bought my additional and will wait patiently as have over past 7 years !!

You really are a 🤡🤣🤣🤣🤡🤡🤡

Wig et al>recommend the filter button. They are simple folks who do not have a scooby doo. The wheel is spinning but the hamster is dead !!

If msuk was half as smart as he thinks he is he’d be twice as smart as he is.

Re binned and good bye, will be back when news arrives.

Correct, buying at 47p in Finland

Will have gone over £1 before Christmas, watch this re-rate in summer/autumn with numerous inflection points as I have described in previous posts

And more good P3 news today for those suffering from Alkaline phosphate deficiency :-)

Congrats AZ

Could be buy-out !!

Xviolet, I have been having those very same thoughts.

Lovely positive Phase 3 results today.

Just added another 6900 to my holding. I think we will see a very strong bounce in SP over the next 12 months.

Wish all FARN holders good health and wealth.

However Juho et al are not really helping my average in Faron at the moment 🤔🤣

Thanks 86KB, we just have to remain patient.

Volume of shares traded on Finnish stock market today approx 440,000 shares, with share price bang on 0.5 Euros = 43p

Once RI completed, believe this will shoot up quickly towards, initially, £1 mark

I look back at the previous couple of raises by them and in Oct 22 and then the Feb 24, the SP on each occasion did a severe positive correction upwards, I am anticipating the same market price behaviour on this occasion. Hope I'm right for once !!!

The science has not changed, as the CEO states:

'In 2025, we continued to make steady progress in advancing our lead asset bexmarilimab and solidifying our position in the field of immunotherapy. Throughout the year, we achieved significant clinical and regulatory milestones and presented continuously improving data from the BEXMAB trial in higher-risk myelodysplastic syndrome (HR MDS), demonstrating the potential of bexmarilimab to overcome treatment resistance in areas of high unmet need.

We are now at a pivotal stage in the development of bexmarilimab. With the proposed offering, we aim to conduct a randomised Phase II trial with bexmarilimab in combination with azacitidine in frontline HR MDS. This trial path and design have been discussed with the FDA, and it is in line with the first FDA guidelines for MDS for the industry published in the second half of 2025. Additionally, we aim to support up to five investigator‑initiated trials (IITs) across multiple solid tumours and blood cancers.

Faron has been engaged in several discussions with potential partners for the future development of bexmarilimab. We believe that reaching a strategic partnership or acquisition of sufficient value to achieve a good return for investors is considerably more likely and more valuable with randomised Phase II data in HR MDS and with more combination data in other indications.

With the results generated to date, we are convinced that bexmarilimab has the potential to become the next standard of care in HR MDS and possible other indications.'

I feel really angry and P***** off with how we have been treated. Really do not know what I should do.

Numerous newsflow will be arriving later this year and next. This will be imo above £1.65p before next June, maybe significantly more. Great that numerous IIT's will be starting soon. Looking forward to the next BEX inflection points. Keep calm and be 'CLEVER'

Yes, BOD have a lot to answer for, down since start of year over 70%, borderline criminal !!! This raise could have been done with a discount when the share was £1.65 @ 25% discount and would have been swallowed up, instead, they just 'suggest' fund raise and let the shorters burn the price !!!! At yesterdays presentation in the Q&A, they did not answer the question about what price RI ...............................................My guess would be 55p

Let's hope he does have a cunning plan.

CEO Juho Jalkanen said: ‘We begin the year with two main themes: advancing bexmarilimab‘s development in HR MDS and demonstrating that our lead asset is also suitable in other indications, especially in solid tumours. In HR MDS, we have already generated some of the best clinical data ever seen. We have adapted our clinical program to hopefully overcome all existing challenges..to eventually secure a positive phase three’.

‘In the broader market context, we believe that the pharmaceutical sector is poised for a resurgence. Major pharma companies are facing a patent cliff, threatening to put a significant portion of their revenues at risk through 2030...The fundamentals concerning the business are solid and industry trends are in our favour...Our time will come.’ he added.

I cannot buy £5K on HL !!!!! Suddenly rationing amount to buy !!

Saoirse : Apologies, if that came across as I thought you were BS'ing, I have written and had something similar a few weeks ago after the fall.

For those who think this is untrue, write an email yourself. I suggest being very polite, without trying to get information that is 'restricted'. I thought the reply was very fair and respectful. I think they are also surprised by the reaction.

Https://www.investegate.co.uk/announcement/mfn/faron-pharmaceuticals-oy-di---farn/faron-s-financial-statements-release-1-januar-/9456873

mportant choices ahead in 2026

I could not be prouder of our team and their accomplishments during the year. At the same time, I look ahead to 2026 with great anticipation and optimism. We begin the year with two main themes: advancing bexmarilimab’s development in HR MDS and demonstrating that our lead asset is also suitable in other indications, especially in solid tumours. In HR MDS, we have already generated some of the best clinical data ever seen. We have adapted our clinical program to hopefully overcome all existing challenges in this space to eventually secure a positive Phase III and the long-awaited approval of a new drug for the treatment of HR MDS, subject to of course positive results.

In the broader market context, we believe that the pharmaceutical sector is poised for a resurgence. Major pharma companies are facing a patent cliff, threatening to put a significant portion of their revenues at risk through 2030. As some key patents expire, these companies face intense pressure to find new blockbuster assets. This is why it is so important for us to keep advancing bexmarilimab across several indications. A main theme for 2026 is to show that bexmarilimab is not just a drug for MDS.

As we have communicated before, we are constantly engaged in in-depth commercial discussions. I remain confident that we will find the right solution when the time is right.

The fundamentals concerning the business are solid and industry trends are in our favour: 1) bexmarilimab is one of the most advanced novel agents in development for HR MDS with some of the best efficacy and safety ever seen, 2) there is a profound need for new treatments in HR MDS, 3) commercial pharma companies are in need of new well selling drug candidates to overcome their patent cliffs, 4) further considerable value creation potential in solid tumours. Our time will come.”